FectoVIR®-LV transfection reagent

Specifications
Overview
Capabilities
All Data
Resources

Specifications

Product information	Ready to use, synthetic and free of any animal-origin component
Applications	Lentiviral vectors (LV) manufacturing using HEK-293 derivative cells cultivated in suspension
Number of transfections	100 mL of FectoVIR^®-LV transfection reagent is sufficient to transfect on average 50 L of cell culture (using standard conditions)
Storage condition	Store FectoVIR^®-LV at 5 °C ± 3°C.  Expiry date is indicated in the certificate of analysis and on the product.
Product documentation	Protocol  Certificate of Analysis  Certificate of origin  Non-hazardous product statement

Overview

Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs.

Discover Polyplus’ complementary DOE service to fast-track optimization of lentivirus production with FectoVIR®-LV.

Ordering Information

Reference Number	Product	Amount of reagent
101000187	FectoVIR®-LV	FectoVIR®-LV 1 mL
101000188	FectoVIR®-LV	FectoVIR®-LV 10 mL
101000189	FectoVIR®-LV	FectoVIR®-LV 100 mL

Want to request a quote

Get Now

Capabilities

Improve lentiviral vector productivity using FectoVIR®-LV

The production of lentiviral vectors for cell and gene therapy is performed using 3rd generation plasmid systems in HEK-293 and derivative cell systems. Transfection reagents are considered as a critical raw material because of its major impact on productivity. Choosing the transfection reagent based on the best titers is a must for process economics and intensification. FectoVIR®-LV increases up to 3-fold functional titers in comparison to other commercially available lentivirus-specific transfection reagents.

Reduce lentiviral vector manufacturing costs using DOE approach

Improving titers is one of the key parameters to increase number of doses per batch and reduce cost per dose. When combined with reduced .consumption of additional critical raw material such as DNA quantity, overall manufacturing costs can be further reduced. FectoVIR^®-LV both allows gain in productivity while reducing by 2-fold DNA consumption. To support our customers, Polyplus offers a comprehensive DOE service to optimize key parameters of transfection step to reach higher titers.

Increase your scale without being limited by the transfection mix

Transient transfection at large scale comes with challenges, of which transfer of transfection mix within an optimal trimeframe. This step can be a limit if the transfection reagent is not adapted for large scale manufacturing. FectoVIR^®-LV has been designed to increase complex stability and decrease complex volume allowing sufficient time to transfer the mix into large bioreactors (>200 L). FectoVIR^®-LV has proven its efficiency using the recommended 5% complexation volume and 30 min of complexation volume, which can be even further optimized to fit your process. Polyplus recommends performing a DOE study adapted to your system.